Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models.

Ruth MM, Magombedze G, Gumbo T, Bendet P, Sangen JJN, Zweijpfenning S, Hoefsloot W, Pennings L, Koeken VACM, Wertheim HFL, Lee PS, van Ingen J, Deshpande D.

J Antimicrob Chemother. 2019 Apr 30. pii: dkz143. doi: 10.1093/jac/dkz143. [Epub ahead of print]

PMID:
31039251
2.

Outcomes of hypertonic saline inhalation as a treatment modality in nontuberculous mycobacterial pulmonary disease.

Huiberts A, Zweijpfenning SMH, Pennings LJ, Boeree MJ, van Ingen J, Magis-Escurra C, Hoefsloot W.

Eur Respir J. 2019 Apr 18. pii: 1802143. doi: 10.1183/13993003.02143-2018. [Epub ahead of print] No abstract available.

PMID:
31000680
3.

Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease.

Zweijpfenning SMH, Schildkraut JA, Coolen JPM, Ruesen C, Koenraad E, Janssen A, Ruth MM, de Jong AS, Kuipers S, Aarnoutse RE, Magis-Escurra C, Hoefsloot W, van Ingen J.

Eur Respir J. 2019 Apr 18. pii: 1900118. doi: 10.1183/13993003.00118-2019. [Epub ahead of print] No abstract available.

PMID:
31000671
4.

Nontuberculous mycobacterial pulmonary disease and Aspergillus co-infection: Bonnie and Clyde?

Geurts K, Zweijpfenning SMH, Pennings LJ, Schildkraut JA, Boeree MJ, Magis-Escurra C, van der Lee H, Verweij PE, Hoefsloot W, van Ingen J.

Eur Respir J. 2019 Apr 7. pii: 1900117. doi: 10.1183/13993003.00117-2019. [Epub ahead of print] No abstract available.

PMID:
30956203
5.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring.

Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3.

6.

High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.

Seijger C, Hoefsloot W, Bergsma-de Guchteneire I, Te Brake L, van Ingen J, Kuipers S, van Crevel R, Aarnoutse R, Boeree M, Magis-Escurra C.

PLoS One. 2019 Mar 14;14(3):e0213718. doi: 10.1371/journal.pone.0213718. eCollection 2019.

7.

A case promoting use of ultrasound-guided sampling techniques to correctly diagnose MDR-TB in children.

van Aerde KJ, van der Heijden EHFM, Henriet SS, Merkus PJ, Magis-Escurra C, Hoefsloot W, van Ingen J, van der Flier M.

Int J Tuberc Lung Dis. 2019 Feb 1;23(2):236-238. doi: 10.5588/ijtld.18.0322.

PMID:
30808457
8.

Bilateral vs. unilateral repetitive transcranial magnetic stimulation to treat neuropathic orofacial pain: A pilot study.

Henssen DJHA, Hoefsloot W, Groenen PSM, Van Cappellen van Walsum AM, Kurt E, Kozicz T, van Dongen R, Schutter DJLG, Bartels RHMA.

Brain Stimul. 2019 May - Jun;12(3):803-805. doi: 10.1016/j.brs.2019.02.001. Epub 2019 Feb 7. No abstract available.

PMID:
30772275
9.

Implementation of Semiautomated Antimicrobial Susceptibility Interpretation Hardware for Nontuberculous Mycobacteria May Overestimate Susceptibility.

Rockland M, Ruth MM, Aalders N, Pennings L, Hoefsloot W, Wattenberg M, van Ingen J.

J Clin Microbiol. 2019 Mar 28;57(4). pii: e01756-18. doi: 10.1128/JCM.01756-18. Print 2019 Apr.

PMID:
30760530
10.

A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.

Ruth MM, Sangen JJN, Remmers K, Pennings LJ, Svensson E, Aarnoutse RE, Zweijpfenning SMH, Hoefsloot W, Kuipers S, Magis-Escurra C, Wertheim HFL, van Ingen J.

J Antimicrob Chemother. 2019 Apr 1;74(4):935-943. doi: 10.1093/jac/dky526.

PMID:
30649327
11.

Clofazimine does not lead to significant QT interval prolongation: a multicentre study.

Zweijpfenning SMH, van Groningen H, van Ingen J, Magis-Escurra C, Boeree MJ, Wagner D, Bax H, Andrejak C, Wener R, Rahman A, Kunst H, Lorent N, Brouwer MA, Hoefsloot W; NTM-NET.

Eur Respir J. 2018 Nov 1;52(5). pii: 1801386. doi: 10.1183/13993003.01386-2018. Print 2018 Nov. No abstract available.

PMID:
30385602
12.

Dissemination of localized Mycobacterium malmoense infection in an immunocompromised patient.

Zweijpfenning SMH, Schipper L, Duurkens VAM, Harbers JB, van Ingen J, Hoefsloot W.

Int J Infect Dis. 2018 Nov;76:35-37. doi: 10.1016/j.ijid.2018.08.019. Epub 2018 Sep 7.

13.

Minocycline Has No Clear Role in the Treatment of Mycobacterium abscessus Disease.

Ruth MM, Sangen JJN, Pennings LJ, Schildkraut JA, Hoefsloot W, Magis-Escurra C, Wertheim HFL, van Ingen J.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01208-18. doi: 10.1128/AAC.01208-18. Print 2018 Oct.

14.

Geographic Distribution of Nontuberculous Mycobacteria Isolated from Clinical Specimens: A Systematic Review.

Zweijpfenning SMH, Ingen JV, Hoefsloot W.

Semin Respir Crit Care Med. 2018 Jun;39(3):336-342. doi: 10.1055/s-0038-1660864. Epub 2018 Aug 2.

PMID:
30071548
15.

Mycobacterium avium complex bacteria remain viable in sputum during storage and refrigeration.

Pennings LJ, Zweijpfenning S, Ruth MM, Wattenberg M, Boeree MJ, Hoefsloot W, van Ingen J.

Diagn Microbiol Infect Dis. 2018 Dec;92(4):309-310. doi: 10.1016/j.diagmicrobio.2018.06.017. Epub 2018 Jun 27.

PMID:
30025970
16.

Image enhancement technology in bronchoscopy: a prospective multicentre study in lung cancer.

van der Heijden EHFM, Candoli P, Vasilev I, Messi A, Pérez Pallarés J, Yablonskii P, van der Vorm A, Schuurbiers OCJ, Hoefsloot W.

BMJ Open Respir Res. 2018 May 18;5(1):e000295. doi: 10.1136/bmjresp-2018-000295. eCollection 2018.

17.

High mortality in patients with Mycobacterium avium complex lung disease: a systematic review.

Diel R, Lipman M, Hoefsloot W.

BMC Infect Dis. 2018 May 3;18(1):206. doi: 10.1186/s12879-018-3113-x.

18.

Pulmonary disease by non-tuberculous mycobacteria - clinical management, unmet needs and future perspectives.

Larsson LO, Polverino E, Hoefsloot W, Codecasa LR, Diel R, Jenkins SG, Loebinger MR.

Expert Rev Respir Med. 2017 Dec;11(12):977-989. doi: 10.1080/17476348.2017.1386563. Epub 2017 Oct 10. Review.

PMID:
28967797
19.

Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.

Zweijpfenning S, Kops S, Magis-Escurra C, Boeree MJ, van Ingen J, Hoefsloot W.

Respir Med. 2017 Oct;131:220-224. doi: 10.1016/j.rmed.2017.08.031. Epub 2017 Sep 1.

PMID:
28947034
20.

Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.

van Altena R, Akkerman OW, Alffenaar JC, Kerstjens HA, Magis-Escurra C, Boeree MJ, van Soolingen D, de Lange WC, Bolhuis MS, Hoefsloot W, de Vries G, van der Werf TS.

Eur Respir J. 2016 Dec;48(6):1800-1802. doi: 10.1183/13993003.01208-2016. Epub 2016 Oct 6. No abstract available.

21.

Regimens for nontuberculous mycobacterial lung disease lack early bactericidal activity.

Slaats MH, Hoefsloot W, Magis-Escurra C, Boeree MJ, Wattenberg M, Kuipers S, van Ingen J.

Eur Respir J. 2016 Mar;47(3):1000-2. doi: 10.1183/13993003.00925-2015. Epub 2015 Dec 2. No abstract available.

22.

High definition bronchoscopy: a randomized exploratory study of diagnostic value compared to standard white light bronchoscopy and autofluorescence bronchoscopy.

van der Heijden EH, Hoefsloot W, van Hees HW, Schuurbiers OC.

Respir Res. 2015 Mar 7;16:33. doi: 10.1186/s12931-015-0193-7.

23.

Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence.

van Ingen J, Ferro BE, Hoefsloot W, Boeree MJ, van Soolingen D.

Expert Rev Anti Infect Ther. 2013 Oct;11(10):1065-77. doi: 10.1586/14787210.2013.830413. Review.

PMID:
24124798
24.

Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance.

van Ingen J, Hoefsloot W, Mouton JW, Boeree MJ, van Soolingen D.

Int J Antimicrob Agents. 2013 Jul;42(1):80-2. doi: 10.1016/j.ijantimicag.2013.03.010. Epub 2013 May 9.

PMID:
23664674
25.

The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study.

Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, Beylis N, Boeree MJ, Cacho J, Chihota V, Chimara E, Churchyard G, Cias R, Daza R, Daley CL, Dekhuijzen PN, Domingo D, Drobniewski F, Esteban J, Fauville-Dufaux M, Folkvardsen DB, Gibbons N, Gómez-Mampaso E, Gonzalez R, Hoffmann H, Hsueh PR, Indra A, Jagielski T, Jamieson F, Jankovic M, Jong E, Keane J, Koh WJ, Lange B, Leao S, Macedo R, Mannsåker T, Marras TK, Maugein J, Milburn HJ, Mlinkó T, Morcillo N, Morimoto K, Papaventsis D, Palenque E, Paez-Peña M, Piersimoni C, Polanová M, Rastogi N, Richter E, Ruiz-Serrano MJ, Silva A, da Silva MP, Simsek H, van Soolingen D, Szabó N, Thomson R, Tórtola Fernandez T, Tortoli E, Totten SE, Tyrrell G, Vasankari T, Villar M, Walkiewicz R, Winthrop KL, Wagner D; Nontuberculous Mycobacteria Network European Trials Group.

Eur Respir J. 2013 Dec;42(6):1604-13. doi: 10.1183/09031936.00149212. Epub 2013 Apr 18.

26.

Prevalence of nontuberculous mycobacteria in COPD patients with exacerbations.

Hoefsloot W, van Ingen J, Magis-Escurra C, Reijers MH, van Soolingen D, Dekhuijzen RP, Boeree MJ.

J Infect. 2013 Jun;66(6):542-5. doi: 10.1016/j.jinf.2012.12.011. Epub 2013 Jan 5. No abstract available.

PMID:
23298891
27.

No human transmission of Mycobacterium malmoense in a perfect storm setting.

Hoefsloot W, Boeree MJ, van Nieuwkoop C, Bernards AT, Savelkoul PH, van Ingen J, van Soolingen D.

Eur Respir J. 2012 Dec;40(6):1576-8. doi: 10.1183/09031936.00096312. No abstract available.

28.

Hypersensitivity pneumonitis caused by Mycobacterium avium subsp. hominissuis in a hot tub, as proven by IS1245 RFLP and rep-PCR typing.

van der Zanden RJ, Magis-Escurra C, de Lange WC, Hoefsloot W, Boeree MJ, van Ingen J, van Soolingen D.

Int J Mycobacteriol. 2012 Sep;1(3):152-4. doi: 10.1016/j.ijmyco.2012.07.006. Epub 2012 Aug 24.

29.

Characterization of a novel variant of Mycobacterium chimaera.

van Ingen J, Hoefsloot W, Buijtels PC, Tortoli E, Supply P, Dekhuijzen PN, Boeree MJ, van Soolingen D.

J Med Microbiol. 2012 Sep;61(Pt 9):1234-9. doi: 10.1099/jmm.0.045070-0. Epub 2012 Jun 14.

PMID:
22700551
30.

Mycobacterium genavense in the Netherlands: an opportunistic pathogen in HIV and non-HIV immunocompromised patients. An observational study in 14 cases.

Hoefsloot W, van Ingen J, Peters EJ, Magis-Escurra C, Dekhuijzen PN, Boeree MJ, van Soolingen D.

Clin Microbiol Infect. 2013 May;19(5):432-7. doi: 10.1111/j.1469-0691.2012.03817.x. Epub 2012 Mar 22.

31.

The changing pattern of clinical Mycobacterium avium isolation in the Netherlands.

van Ingen J, Hoefsloot W, Dekhuijzen PN, Boeree MJ, van Soolingen D.

Int J Tuberc Lung Dis. 2010 Sep;14(9):1176-80.

PMID:
20819265
32.

[Nontuberculous mycobacteria: clinically relevant].

van Ingen J, Hoefsloot W, de Lange WC, Magis-Escurra C, Dekhuijzen PN, Boeree MJ, van Soolingen D.

Ned Tijdschr Geneeskd. 2010;154:A1178. Review. Dutch.

PMID:
20482903
33.

Renal infarction after cocaine abuse: a case report and review.

Hoefsloot W, de Vries RA, Bruijnen R, Bosch FH.

Clin Nephrol. 2009 Sep;72(3):234-6. Review.

PMID:
19761732
34.

Clinical relevance of Mycobacterium malmoense isolation in The Netherlands.

Hoefsloot W, van Ingen J, de Lange WC, Dekhuijzen PN, Boeree MJ, van Soolingen D.

Eur Respir J. 2009 Oct;34(4):926-31. doi: 10.1183/09031936.00039009. Epub 2009 Apr 22.

35.

Quiz page March 2009: A 58-year-old man with chronic hepatitis B, nephrotic syndrome, and a papulosquamous rash.

Hoefsloot W, Reichert L, Meijer J, Richter C.

Am J Kidney Dis. 2009 Mar;53(3):xxxv-xxxvii. doi: 10.1053/j.ajkd.2008.11.020. No abstract available.

PMID:
19231733
36.

Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands.

van Ingen J, Bendien SA, de Lange WC, Hoefsloot W, Dekhuijzen PN, Boeree MJ, van Soolingen D.

Thorax. 2009 Jun;64(6):502-6. doi: 10.1136/thx.2008.110957. Epub 2009 Feb 12.

PMID:
19213773
37.

The rising incidence and clinical relevance of Mycobacterium malmoense: a review of the literature.

Hoefsloot W, Boeree MJ, van Ingen J, Bendien S, Magis C, de Lange W, Dekhuijzen PN, van Soolingen D.

Int J Tuberc Lung Dis. 2008 Sep;12(9):987-93. Review.

PMID:
18713494
38.

Mycobacterium xenopi clinical relevance and determinants, the Netherlands.

van Ingen J, Boeree MJ, de Lange WC, Hoefsloot W, Bendien SA, Magis-Escurra C, Dekhuijzen R, van Soolingen D.

Emerg Infect Dis. 2008 Mar;14(3):385-9. doi: 10.3201/eid1403.061393.

39.

Systematic review of quantitative clinical gait analysis in patients with dementia.

van Iersel MB, Hoefsloot W, Munneke M, Bloem BR, Olde Rikkert MG.

Z Gerontol Geriatr. 2004 Feb;37(1):27-32.

PMID:
14991293
40.

Relative contributions of central and peripheral factors to fatigue during a maximal sustained effort.

Schillings ML, Hoefsloot W, Stegeman DF, Zwarts MJ.

Eur J Appl Physiol. 2003 Nov;90(5-6):562-8. Epub 2003 Aug 5.

PMID:
12905050

Supplemental Content

Loading ...
Support Center